Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9954288 | 0.88 | OPRM1 (0.42) | KCNA5KCNH2OPRM1OPRK1CREBBP | |
| SCHEMBL9953640 | 0.81 | NPBWR1 (0.41) | OPRM1OPRK1CREBBPMAPK1 | |
| SCHEMBL9955165 | 0.80 | CREBBP (0.37) | CREBBPPLATKDM5BGABRA1GABRG2 | |
| SCHEMBL9954364 | 0.77 | ATM (0.42) | CREBBP | |
| SCHEMBL9953649 | 0.73 | RAB9A (0.51) | CREBBP | |
| SCHEMBL10036282 | 0.73 | RAB9A (0.51) | CREBBP | |
| SCHEMBL9954004 | 0.73 | RAB9A (0.51) | CREBBP | |
| SCHEMBL16588906 | 0.72 | USP2 (0.40) | OPRM1OPRK1CREBBPMAPK1 | |
| SCHEMBL15305627 | 0.71 | PTGS2 (0.48) | CREBBP | |
| SCHEMBL15305629 | 0.71 | MET (0.43) | CREBBPADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654752-B1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PF MEDICAMENT (FR) | 2015-05-27 | — | — | EP | disclosed |
| US-8993569-B2 | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | PIERRE FABRE MEDICAMENT (FR) | 2015-03-31 | — | — | US | disclosed |
| EP-2654752-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | Pierre Fabre Medicament (FR) | 2013-10-30 | — | — | EP | disclosed |
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012085001-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | KCNA4, KCNK4, KCNQ4 | KCNA5 9/4885KCNH2 11/4885OPRM1 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.